ROCKVILLE, MD / ACCESS Newswire / October 2, 2026 / American Gene Technologies (“AGT”), a clinical-stage biotech developing AGT103-T – the only program to demonstrate elimination of the HIV viral reservoir in humans – will present at the National Investment Banking Association (NIBA) 153rd Investment Conference on October 6-7, 2026.
AGT is raising $55 million to fund its Phase 2 trial of this one-time, gene-modified T-cell therapy targeting a functional cure for HIV in a $40 billion annual market. Backed by a successful Phase 1 trial, FDA Fast Track designation, 60+ patents.
AGT will be available for one-on-one investor meetings on October 7. To schedule a meeting, contact Drew Palin, President, at wdpalin@americangene.com or visit nibanet.org for details.
SOURCE: American Gene Technologies
View the original press release on ACCESS Newswire
Ten years after the veteran nonprofit was founded, the woman it once served will lead…
Dividend intended to provide dilution protection to Jaguar shareholders as company continues evaluation of strategic…
SOBR Provides Clarity and Considers Future Options DENVER, CO / ACCESS Newswire / October 2,…
Every Detail Matters: MagnaFlow Helps Put the Finishing Touch on Project REBORN's 5-Inch Exhaust NORTH…
CEO David Antelo outlines a new path focused on technology validation, smaller facilities and domestic…
The sale of Holly View Apartments reflects founder and CEO Raphael Toledano's disciplined approach to…